Immunotherapy for rhinitis

Current Allergy and Asthma Reports

Volumn 3, Issue 3, 2003, Pages 204-209

  Malling, Hans Jørgen ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; ANTIALLERGIC AGENT; BUDESONIDE; CALCIUM PHOSPHATE; CORTICOSTEROID; CYTOKINE; PLACEBO; POLLEN ANTIGEN; STEROID;

ALLERGIC RHINITIS; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATION; MEDICAL DOCUMENTATION; MUCOSA; PHENOTYPE; PUBLICATION; REVIEW; SCORING SYSTEM; SENSITIZATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; TH1 CELL; HAY FEVER; IMMUNOLOGY; METHODOLOGY; PERENNIAL RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0037645149     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-003-0040-7     Document Type: Review

References (37)

1. Sly RM: Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999, 82:233-248.
2. Bousquet J, Van Cauvenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:147-334.
3. Linna O, Kokkonen J, Lukin M: A 10-year prognosis for childhood allergic rhinitis. Acta Paedriatr 1992, 81:100-102.
4. Settipane RJ, Hagy GW, Settipane GA: Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994, 15:21-25.
5. Madonini E, Briatico Vangosa G, Pappacoda A, et al.: Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 1987, 79:358-363.
6. Braman SS, Barrows AA, DeCotiis BA, et al.: Airway hyperresponsiveness in allergic rhinitis: a risk factor for asthma. Chest 1987, 91:671-674.
7. Malling H-J: Immunotherapy as an effective tool in allergy treatment. Allergy 1998, 53:461-472.
8. Bousquet J, Lockey RF, Malling H-J (eds): WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998, 53(Suppl 44):1-42.
9. Malling H-J, Abreu-Nogueira J, Alvarez-Cuesta E, et al.: Local immunotherapy: position paper from EAACI & ESPACI. Allergy 1998, 53:933-944.
10. Malling H-J: Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol 2002, 2:523-531.
11. Ross RN, Nelson HS, Finegold I: Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther 2000, 22:342-350.
12. Walker SM, Pajno GB, Torres Lima M, et al.: Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomised controlled trial. J Allergy Clin Immunol 2001, 107:87-93.
13. Leynadier F, Banoun L, Dollois B, et al.: Immunotherapy with calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001, 31:988-996.
14. Rak S, Heinrich C, Jacobsen L, et al.: A double-blind, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001, 108:921-928.
15. Bødtger U, Poulsen LK, Jacobi H, Malling H-J: The safety and efficacy of subcutaneous birch pollen immunotherapy: a one-year, randomized, double-blind, placebo-controlled study. Allergy 2002, 57:297-305.
16. Guez S, Vatrinet C, Fadel R, Andre C: House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000, 55:369-375.
17. Pajno GB, Morabito L, Barberio G, Parmiani S: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000, 55:842-849.
18. Cafferelli C, Sensi LG, Marcucci F, Cavagni G: Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000, 55:1142-1147.
19. Bahceciler NN, Isik U, Barlan IB, Basaran MM: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001, 32:49-55.
20. Voltolini S, Modena P, Minale P, et al.: Sublingual immunotherapy in tree pollen allergy: double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch, and hazel) administered by a rush schedule. Allergol Immunopathol (Madr) 2001, 29:103-110.
21. Ariano R, Spadolini I, Panzani RC: Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica: a double blind study. Allergol Immunopathol 2001, 29:238-244.
22. Torres Lima M, Wilson D, Pitkin L, et al.: Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002, 32:507-514.
23. Quirino T, Iemoli E, Siciliani E, et al.: Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996, 26:1253-1261.
24. Mungan D, Misirligil Z, Gurbuz L: Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999, 82:485-490.
25. Khinchi MS, Poulsen LK, Carat F, et al.: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.
26. Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
27. Varney VA, Gaga M, Frew AJ, et al.: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991, 302:265-269.
28. Eng PA, Reinhold M, Gnehm HPE: Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002, 57:306-312.
29. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al.: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy 2001, 31:1295-1302.
30. Pajno GB, Barberio G, de Luca Fr, et al.: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001, 31:1392-1397.
31. Möller C, Dreborg S, Ferdousi HA, et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002, 109:251-256.
32. Durham SR, Ying S, Varney VA: Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996, 97:1356-1365.
33. Durham SR, Varney VA, Gaga M, et al.: Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy, 1999, 29:1490-1496.
34. Wachholz PA, Nouri-Aria KT, Wilson DR, et al.: Grass pollen immunotherapy for hay fever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002, 105:56-62.
35. Wilson DR, Irani A-MA, Walker SM, et al.: Grass pollen immunotherapy inhibits seasonal increase in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001, 31:1705-1713.
36. Wilson DR, Nouri-Aria KT, Walker SM, et al.: Grass pollen immunotherapy: symptomatic improvement correlates with reduction in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001, 107:971-976.
37. Erel F, Karaayvaz M, Caliskaner AZ, et al.: Effects of allergen immunotherapy on the nasal mucosa in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2000, 10:14-19.